BioLife Solutions, Inc. (NASDAQ:BLFS) Insider Sarah Aebersold Sells 5,632 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) insider Sarah Aebersold sold 5,632 shares of the firm’s stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $24.96, for a total value of $140,574.72. Following the completion of the sale, the insider now owns 45,860 shares in the company, valued at approximately $1,144,665.60. This represents a 10.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Sarah Aebersold also recently made the following trade(s):

• On Monday, March 17th, Sarah Aebersold sold 2,695 shares of BioLife Solutions stock. The stock was sold at an average price of $25.44, for a total value of $68,560.80.
• On Tuesday, March 11th, Sarah Aebersold sold 1,091 shares of BioLife Solutions stock. The shares were sold at an average price of $25.00, for a total transaction of $27,275.00.
• On Monday, January 6th, Sarah Aebersold sold 240 shares of BioLife Solutions stock. The shares were sold at an average price of $27.02, for a total transaction of $6,484.80.

BioLife Solutions Stock Performance

BLFS opened at $25.48 on Thursday. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. The firm has a market cap of $1.20 billion, a PE ratio of -24.04 and a beta of 2.04. The business has a fifty day simple moving average of $26.48 and a 200-day simple moving average of $25.49. BioLife Solutions, Inc. has a fifty-two week low of $14.84 and a fifty-two week high of $29.55.

BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.32. The business had revenue of $22.71 million during the quarter, compared to analyst estimates of $21.73 million. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. During the same quarter last year, the company posted ($0.21) EPS. As a group, equities analysts predict that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on BLFS shares. HC Wainwright upped their price target on shares of BioLife Solutions from $27.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, March 6th. StockNews.com upgraded BioLife Solutions from a “sell” rating to a “hold” rating in a research report on Wednesday. Northland Securities increased their price target on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a research note on Wednesday, January 8th. Benchmark reissued a “buy” rating and issued a $30.00 price objective on shares of BioLife Solutions in a research note on Thursday, December 19th. Finally, KeyCorp raised their target price on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $29.86.

Hedge Funds Weigh In On BioLife Solutions

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC purchased a new stake in shares of BioLife Solutions in the fourth quarter valued at $26,000. Mark Sheptoff Financial Planning LLC acquired a new stake in BioLife Solutions during the 3rd quarter worth about $28,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in BioLife Solutions during the 4th quarter valued at about $31,000. Quest Partners LLC acquired a new position in shares of BioLife Solutions in the 3rd quarter valued at about $57,000. Finally, 1620 Investment Advisors Inc. lifted its position in shares of BioLife Solutions by 41.7% in the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider’s stock worth $60,000 after purchasing an additional 675 shares in the last quarter. Institutional investors and hedge funds own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.